Evaluation Study of Medical-Social Collaboration Model for Middle-aged and Older Adults With Depressive Symptoms
Launched by THE UNIVERSITY OF HONG KONG · Jul 11, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help middle-aged and older adults who are feeling mild to moderate symptoms of depression while they wait for their first appointment with a psychiatrist. The study wants to see if a program that combines medical care with social support can reduce feelings of depression better than just giving people a self-help booklet. Besides depression, the study will also look at whether this program helps reduce anxiety, loneliness, negative thinking, and self-criticism, while improving confidence, resilience, overall well-being, and how often people use healthcare services.
To take part, you must be waiting for psychiatric services through the Hospital Authority, have some symptoms of depression, and be able to give your consent. People with certain conditions like autism, intellectual disabilities, schizophrenia, bipolar disorder, Parkinson’s disease, or dementia, or those at immediate risk of suicide, cannot join right now. Participants will either receive support through the medical-social program that includes step-by-step counseling based on cognitive-behavioral therapy (CBT) or get a self-help booklet. Everyone will complete short surveys about their mental health and use of health services every three months until their first psychiatric appointment. This study is currently recruiting people of all genders aged 16 and older.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Currently awaiting psychiatric services provided by the Hospital Authority
- • Have depressive symptoms of at least mild severity
- • Able to provide informed consent
- Exclusion Criteria:
- • A known history of autism spectrum disorder, intellectual disability, schizophrenia-spectrum disorder, bipolar disorder, Parkinson's disease, or dementia
- • Imminent suicidal risk (temporary exclusion)
- • Communication difficulties that preclude participation
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Terry YS Lum, PhD
Principal Investigator
The University of Hong Kong
Gloria HY Wong, PhD
Principal Investigator
University of Reading
Wai Chi Chan, MBChB
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported